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Abstract
The study of families with rare inherited forms of hypo- and hyper-tension has been one of the most successful
strategies to probe the molecular pathophysiology of blood pressure control and has revealed dysregulation of
distal nephron Na+ reabsorption to be a common mechanism. FHHt (familial hyperkalaemic hypertension; also
known as Gordon’s syndrome) is a salt-dependent form of hypertension caused by mutations in the regulators of
the thiazide-sensitive Na+ –Cl− co-transporter NCC [also known as SLC12A3 (solute carrier family 12 member 3)]
and is effectively treated by thiazide diuretics and/or dietary salt restriction. Variation in at least four genes can
cause FHHt, including WNK1 [With No lysine (=K) 1] and WNK4, KLHL3 (kelch-like family member 3), and CUL3
(cullin 3). In the present study we have identified novel disease-causing variants in CUL3 and KLHL3 segregating in
63% of the pedigrees with previously unexplained FHHt, confirming the importance of these recently described FHHt
genes. We have demonstrated conclusively, in two unrelated affected individuals, that rare intronic variants in CUL3
cause the skipping of exon 9 as has been proposed previously. KLHL3 variants all occur in kelch-repeat domains
and so probably disrupt WNK complex binding. We have found no evidence of any plausible disease-causing
variants within SLC4A8 (an alternative thiazide-sensitive sodium transporter) in this population. The results of the
present study support the existing evidence that the CUL3 and KLHL3 gene products are physiologically important
regulators of thiazide-sensitive distal nephron NaCl reabsorption, and hence potentially interesting novel
anti-hypertensive drug targets. As a third of our non-WNK FHHt families do not have plausible CUL3 or KLHL3
variants, there are probably additional, as yet undiscovered, regulators of the thiazide-sensitive pathways.
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INTRODUCTION
Hypertension is estimated to contribute 3.5-fold more to the total
global disease burden of cardiovascular disease than smoking
and 1.6-fold that of hypercholesterolaemia. Worldwide, 20 % of
deaths in men, 24 % of deaths in women, 62 % of strokes and
Abbreviations: CUL3, cullin 3; FHHt, familial hyperkalaemic hypertension; GAN, gigaxonin; IBD, identity by descent; KLHL3, kelch-like family member 3; NCC, Na+ –Cl− co-
transporter; NGS, next-generation sequencing; SLC, solute carrier; SNP, single nucleotide polymorphism; SPAK, STE20/SPS1-related proline/alanine-rich kinase; STE20, sterile 20;
WNK, With No lysine (=K).
Correspondence: Dr Mark Glover (email mark.glover@nottingham.ac.uk).
49 % of heart disease are attributable to blood pressure [1–3]. The
current limitations in anti-hypertensive therapeutics are perhaps
not surprising since for most affected individuals the molecular
mechanisms driving their hypertension remain undefined.
Although rare, Mendelian forms of hypo- and hyper-
tension represent experiments of Nature that have informed our
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understanding of the physiology of the distal nephron. Remark-
ably, given the variety of physiological systems that affect arterial
pressure, all of these Mendelian syndromes for which the molecu-
lar mechanism is understood converge around a common theme:
distal nephron sodium wasting in hypotensive syndromes and
excessive sodium reabsorption in hypertensive conditions [4].
Although the amiloride-sensitive ENaC (epithelial sodium
channel) has classically dominated research interests, NaCl reab-
sorption via the thiazide-sensitive Na+ –Cl− co-transporter NCC
[also known as SLC12A3 (solute carrier family 12 member 3)]
is at least as important [5]. Thiazide diuretics are potent anti-
hypertensive agents [6] and mimic the effects of loss-of-function
mutations of NCC observed in the hypotensive monogenic syn-
drome of Gitelman [7]. Moreover, the heritable condition of FHHt
(familial hyperkalaemic hypertension) results from increased so-
dium reabsorption via NCC and is effectively ameliorated by
thiazide diuretics and/or dietary sodium restriction [8].
FHHt is a salt-sensitive hypertension characterized by hyper-
kalaemic acidosis and exquisite sensitivity to low-dose thiazide
diuretics [8,9]. As in Liddle’s syndrome [10], significant inter-
and intra-pedigree phenotypic variation is observed clinically
[11]. Causative variants have been identified in WNK1 [With No
lysine (=K) 1] and WNK4, KLHL3 (kelch-like family member
3), and CUL3 (cullin 3) [12–15], but not within the NCC itself
[16]. Variants are inherited in an autosomal dominant or recessive
manner depending on the gene involved and can also occur de
novo [8,14].
The current model for the regulation of NCC is complex and
involves a scaffold of at least 12 interacting proteins centred on
a WNK signalling cascade, with intermediary STE20 (sterile
20) kinases [SPAK (STE20/SPS1-related proline/alanine-rich
kinase) and OSR1 (oxidative stress-responsive kinase-1)] ac-
tivated by WNKs which in turn activate NCC [17–19]. CUL3
and KLHL3 are both components of the cullin/Ring E3 ligase
ubiquitination pathway and at least some variants of KLHL3
appear to affect NCC via the control of WNK1 ubiquitination
[15,20].
We have identified previously three FHHt pedigrees carry-
ing WNK4 mutations (D564H, E562K and Q565E) [21], but
none carrying WNK1 mutations. To assess whether our remain-
ing pedigrees with FHHt and without WNK1/4 mutations had
either CUL3 or KLHL3 mutations, we undertook NGS (next-
generation sequencing) of these genes and also screened an al-
ternative thiazide-sensitive sodium transporter (SLC4A8) hypo-
thesized to be an additional candidate [14].
MATERIALS AND METHODS
Study population
The present study was carried out in accordance with the Declar-
ation of Helsinki (2013) of the World Medical Association. Study
participants with an FHHt phenotype were identified through ter-
tiary specialist hypertension clinics in the U.K. and Australia.
Diagnosis of FHHt was confirmed by the authors. All affected
patients were Caucasian and shared a phenotype of persistent
hyperkalaemia (plasma potassium >5.0 mmol/l in blood collec-
ted without stasis) and hypertension (>140/90 mmHg for adults)
following exclusion of the relevant co-morbidities and pharma-
cotherapies. Detailed phenotypes of the affected individuals are
given in Supplementary Figure S1 (at http://www.clinsci.org/
cs/126/cs1260721add.htm). All non-affected individuals demon-
strated plasma potassium<5 mM/l. The disparity in ages preven-
ted comparison of age-related blood pressure between affected
and non-affected individuals. DNA was extracted using a stand-
ard method from venous blood acquired following informed con-
sent (Princess Alexandra Hospital Human Research Ethics Com-
mittee ID EC00 167 in Australia and National Research Ethics
Committee reference 12/EM/0317 in the U.K.).
DNA analysis
CUL3, KLHL3 and SLC4A8 genes were sequenced in the
affected proband of each family using NGS. PCR ampl-
icons covering all coding exons and exon/intron boundar-
ies were prepared from genomic DNA (Fluidigm Access
ArrayTM; the amplicons used are listed in Supplementary Table
S1 at http://www.clinsci.org/cs/126/cs1260721add.htm) and se-
quenced on the Illumina HiSeq platform. Reads were aligned to
the human reference sequence hg19 using the Burrows–Wheeler
Aligner, and the Genome Analysis Toolkit was used for base
recalibration, local realignment and variant calling, following
published best practice guidelines, and as described previously
[22]. Variants were filtered for rarity and protein consequence:
variants altering the protein-coding sequence [missense and non-
sense SNPs (single nucleotide polymorphisms), insertions or de-
letions, or intronic variants at the exon/intron boundary] that
were absent from public databases [dbSNP, 1000 Genomes and
the NHLBI ESP (National Heart, Lung, and Blood Institute Ex-
ome Sequencing Project) Exome Variant Server] were considered
candidates. All candidates detected by NGS were confirmed in
the proband and assessed for segregation in the pedigree using
Sanger sequencing. Variants are reported using Human Genome
Variation Society standard nomenclature (http://www.hgvs.org/
mutnomen/). The reference sequences used for each gene and pro-
tein are listed in Supplementary Table S2 (at http://www.clinsci.
org/cs/126/cs1260721add.htm).
RNA studies
The functional effects of putative splice variants were con-
firmed using RNA studies. Peripheral blood mononuclear cell
RNA was isolated from 5 ml of whole blood using a PAXgene
blood RNA kit (Qiagen) according to the manufacturer’s instruc-
tions. The RNA was then transcribed using a Promega AMV
reverse transcriptase kit (catalogue number A3500) according to
manufacturer’s instructions using either random primers (RT1)
or a CUL3-specific primer (5′-TTATGCTACATATGTGTATAC-
TTTGC-3′; RT2). The resulting cDNA was then PCR-amplified
using exon-specific primers to amplify exons 8–10 of the CUL3
transcript (forward, 5′-TCAACCTCAACTCCAGGTCTCC-3′
and reverse, 5′-TGTTGCCTGAATTCATCCATCG-3′). The PCR
products were run on a 2 % agarose gel to visualize them, excised,
cleaned using a Promega PCR clean-up kit and Sanger-sequenced
on a Beckman CEQ 6800 sequencer. The expected PCR product
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sizes were 338 bp and 167 bp for the exon 8–10 and del9 tran-
scripts respectively.
Paralogue mapping
For each gene we first identified paralogues using pre-defined
Ensembl protein families (http://www.ensembl.org; release 70),
and constructed a multiple sequence alignment using M-
Coffee [23]. Reported Mendelian disease-causing variants (non-
synonymous SNPs causing a single non-terminal amino acid
change) in paralogues of the FHHt genes were identified us-
ing the Human Gene Mutation Database Professional version
(http://www.hgmd.cf.ac.uk; release 2012.3), and mapped to the
equivalent residue of the FHHt gene in the multiple sequence
alignment.
Exon-directed array and identity by descent
analysis
Representative affected individuals in pedigrees 6, 7 and 8 were
genotyped using the Illumina Infinium HumanExome BeadChip
array. Pair-wise IBD (identity by descent) analysis was under-
taken using PLINK version 1.0.7 [24] on the basis of a subset of
27 402 informative autosomal SNPs with a minor allele frequency
>5 %. A proportion of IBD (PI_HAT) <0.05 was considered to
indicate no excess of sharing (i.e. unrelated individuals).
RESULTS
Genetic analysis of 25 affected individuals from 16 families
with FHHt who had already been screened and found negat-
ive for WNK1/4 mutations was performed. A total of 95 % of
the targeted bases were sequenced adequately for variant calling.
The sequencing depth and coverage achieved by gene and exon
are shown in Supplementary Figure S2 (at http://www.clinsci.
org/cs/126/cs1260721add.htm).
Affected individuals (n= 16) from ten of these 16 families
were found to have CUL3 or KLHL3 variants not reported in
the general population (Table 1 and Supplementary Figure S3
at http://www.clinsci.org/cs/126/cs1260721add.htm). We found
no evidence of rare variants in SLC4A8 which segregated with
disease phenotype.
As shown in Table 1 and Supplementary Figure S2, af-
fected individuals from eight pedigrees carried variants that
have been associated previously with FHHt, two in CUL3 and
six in KLHL3. Affected individuals from two pedigrees carried
variants unreported previously in CUL3 (c.1207-12T>A and
c.1377 + 1G>T). In addition an affected individual from ped-
igree 5 was homozygous for a previously reported heterozygous
KLHL3 variant (c.1499G>T; p.G500V) [15]. In keeping with
previous observations, CUL3 mutations were intronic and prob-
ably affected splicing of exon 9, whereas KLHL3 mutations were
non-synonymous exonic SNPs (Supplementary Figures S4 and
S5 at http://www.clinsci.org/cs/126/cs1260721add.htm).
An affected individual from pedigree 1 had an alternative
G>T variant at the same position in CUL3 as one from pedigree
2 (c.1377 + 1G>C; the original proband reported by Gordon et al.
[9]). Both had a severe hyperkalaemic phenotype apparent during Ta
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Figure 1 Demonstration that the CUL3 variants result in splice variation leading to a loss of exon 9 in affected individuals
from pedigree 1 (Ped1) and pedigree 2 (Ped2)
The affected individuals sequenced are highlighted by ∗ in Supplementary Figure S3 (at http://www.clinsci.org/cs/126/
cs1260721add.htm). (A) Reverse transcription–PCR of CUL3 from peripheral blood mononuclear cells demonstrated an
additional (smaller) cDNA band only in the affected individuals. The size of the smaller band was consistent with a
deficiency of exon 9 (difference in band size = 171 bp). PCR primers RT1 (random primers) and RT2 (a CUL3-specific
primer) are detailed in the Materials and methods section. The molecular size is given on the left-hand side in bp. (B)
Sanger sequencing of CUL3 cDNA from the smaller 167 bp band confirmed that exon 9 is skipped in individuals from both
pedigrees. Sequence excerpts from the larger 338 bp band are shown for the wild-type (WT) individual for comparison,
demonstrating the wild-type exon boundaries. Sequencing chromatograms are shown together with the DNA sequence and
amino acid codons above.
childhood despite coming from different families and living on
opposite sides of the globe. Although variants surrounding this
exon 9/intron 9 acceptor splice site have been predicted to affect
splicing of exon 9 [14], the present study has provided the first
evidence of this effect in FHHt patients. Specifically, RNA from
peripheral blood monocytes of the index case in pedigrees 1 and
2 contains exon 9-deficient transcripts from the mutated CUL3
allele (Figure 1).
Pedigrees 6, 7 and 8 all carry the same KLHL3 p.L387P
mutation that segregates completely with an FHHt phenotype,
raising the question whether these families have a common
founder. IBD analysis (Illumina Infinium HumanExome Bead-
Chip) revealed that these pedigrees were no more related than
by chance (PI_HAT = 0.0440), indicating that the mutation has
probably arisen independently in each lineage. Although the
KLHL3 R528H mutation has also been reported in three pedi-
grees [15], it was not established whether they shared a common
founder. Hence in our pedigrees, KLHL3 p.L378P is the most
commonly identified FHHt-causingKLHL3mutation with robust
evidence of independent founder mutations.
To assess the pathogenicity of the KLHL3 variants as-
sociated with FHHt, we used a Paralogue Annotation ap-
proach [25]. KLHL3 is one of a family of evolutionarily re-
lated cytoskeletal BTB/kelch repeat proteins, variation in sev-
eral of which cause Mendelian disease. Using multiple se-
quence alignment to identify structurally and functionally equi-
valent residues across the protein family, we observed that one
of the KLHL3 variants reported previously to be associated
with FHHt [14,15] (KLHL3 p.R384W) co-locates with a re-
ported disease-causing variant in another member of the pro-
tein family KBTBD13 p.R248S {where KBTBD13 is kelch re-
peat and BTB [BR-C (Broad Complex), ttk (tramtrack) and bab
(bric a brac)] (POZ) domain-containing 13}, which is associ-
ated with nemalin myopathy [26]. This suggests that the vari-
ants lie at a functionally important site conserved across the
protein family that is intolerant of sequence variation. Simil-
arly, two of the KLHL3 FHHt variants in our patients (L387P
and A494T) are very close to the location of known disease-
causing variants in GAN (gigaxonin) [27], suggesting that these
too are probably functionally important sites. GAN p.G368 and
p.G474 (at which substitutions are associated with giant ax-
onal neuropathy [27]) are equivalent to KLHL3 p.G388 and
p.G496, and are adjacent to rare variants found in our FHHt
pedigrees.
724 C© The Authors Journal compilation C© 2014 Biochemical Society© 2014 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
KLHL3 and CUL3 in Gordon’s syndrome
DISCUSSION
In the present study we have identified disease-causing variants
in CUL3 and KLHL3 in 63 % of our pedigrees with FHHt who
had been screened and found to be negative for WNK1/4 muta-
tions, confirming recent reports of association betweenCUL3 and
KLHL3 variants and FHHt [14,15]. In the case of CUL3 mutation
at position c.1377 + 1 we report a second variant allele associated
with a similar thiazide-responsive FHHt phenotype, strengthen-
ing further the case for a functional role of aberrant CUL3 func-
tion on sodium reabsorption in the distal nephron. We have also
demonstrated that the predicted exon 9 splicing effect produced
by c.1377 + 1G>T and c.1377 + 1G>A is, in fact, observed.
We have found that KLHL3 p.L387P associated with FHHt in
three unrelated pedigrees, making this the most commonly occur-
ring single FHHt mutation not only within our FHHt consortium,
which includes three FHHt pedigrees carrying different WNK4
mutations (D564H, E562K and Q565E) [21], but also among all
KLHL3 mutations reported to date [14,15]. That KLHL3 vari-
ants in our pedigrees are restricted to kelch repeats, and that
other FHHt-associated KLHL3 variants cluster in these domains
provides further support for disruption of WNK complex binding
as reported previously [20].
Accepting the limitations of bioinformatics tools to predict
pathogenicity, we did not find evidence of probable disease-
causing variants within an alternative thiazide-sensitive sodium
bicarbonate exchanger, SLC4A8, hypothesized as an alternative
genetic candidate for FHHt [14]. A third of our pedigrees with
non-WNK FHHt therefore remain without a genetic diagnosis,
which is somewhat greater than that reported in other pedigree
collections [14,15]. This highlights the genetic heterogeneity of
the FHHt phenotype and the likelihood that additional, as yet
undiscovered, regulators of thiazide-sensitive pathways exist. It
is also worth emphasizing that we set out to identify KLHL3
and CUL3 variants in subjects with a clinical diagnosis of FHHt
on the basis of measurements routinely recorded in the clinic.
Similar data are recorded for unaffected relatives, but because
of the large disparity in ages it is often impossible to provide a
comparison of age-related blood pressure between affected and
non-affected individuals. Nevertheless, all non-affected individu-
als were normokalaemic with a plasma potassium <5 mmol/l,
and we are confident that we have correctly assigned affected
compared with non-affected status within our pedigrees.
Further detailed laboratory and clinical studies are required
to establish whether the effects of the reported heterogeneity
of variant KLHL3 on WNK1 immunoprecipitation and ubiquit-
ination translate into differential effects on thiazide-sensitive
distal nephron sodium trafficking and phenotype within FHHt
[20]. For instance, do patients with KLHL3 A340V and A494T
Gordon’s syndrome have the same CUL3/KLHL3/WNK/SPAK/
NCC pathway abnormalities as those with KLHL3 L387P?
In conclusion we have identified disease-causing variants in
CUL3 and KLHL3 in patients with FHHt screened previously
and found to be negative for WNK1 and WNK4 mutations, but
did not find evidence of such variants in the alternative candidate
SLC4A8. Approximately one-third of our non-WNK patients with
FHHt remain without a molecular diagnosis raising the possibility
that there may be additional regulators of thiazide-sensitive distal
nephron sodium trafficking which remain to be discovered.
CLINICAL PERSPECTIVES
 The present study was performed to acertain whether pedi-
gress with FHHt, but without mutation in WNK1/WNK4, con-
tained mutation in CUL3, KLHL3 or SLC4A8.
 The present study confirms recent findings of CUL3 and
KLHL3 mutations in FHHt and identifies novel disease-
causing variants. This strengthens the argument that these gene
products are physiologically important regulators of distal
nephron NaCl reabsorption via thiazide-sensitive pathways,
and hence are potentially interesting novel anti-hypertensive
drug targets.
 As only 63 % of our non-WNK FHHt families were found to
contain plausibleCUL3 orKLHL3 variants, there are probably
additional, as yet undiscovered, regulators of thiazide-sensitive
pathways.
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Figure S1 Clinical features in FHHt-affected individuals stratified by genotype
(A) Age at diagnosis and serum K+ , HCO3 − and Cl− are shown for FHHt-affected individuals with mutations in CUL3 and
KLHL3. (B) Systolic and diastolic blood pressure (BP) for FHHt-affected individuals of each mutation class is shown as a
function of age.
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KLHL3 and CUL3 in Gordon’s syndrome
Figure S2 Average depth of sequencing for (A) KLHL3, (B) CUL3 and (C) SLC4A8 genes enriched using the Fluidigm
Access ArrayTM by exon
Log10 normalized depth of coverage is shown against DNA position with numbered exons in each case.
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Figure S3 Pedigree structure of the ten kindreds with FHHt and mutations in CUL3 and KLHL3 detailed in Table 1 of the
main text
Affected, unaffected and phenotype-undetermined subjects are denoted by black, white and grey symbols respectively.
Alongside each pedigree, Sanger sequence traces are shown showing the wild-type sequence and the corresponding CUL3
or KLHL3 variant segregating with the affected phenotype within each family. ∗The affected individual whose sequence
is shown; c, the following co-ordinate is of coding DNA. Variants are described using standard Human Genome Variation
Society nomenclature. Reference sequences for each gene are listed in Table S1. Pedigree 1: the affected individual
carries a previously unreported variant disrupting a consensus splice site in CUL3. The lower chromatogram of CUL3
shows that in the affected individual the wild-type guanine at position c.1377 + 1 (the first base of intron 9 at the border
with exon 9) is mutated to thymine in a heterozygous manner compared with the wild-type chromatogram shown above.
The position of this variant is shown in more detail in Figure S5 and full genetic co-ordinates are detailed in Table 1 of the
main text. Pedigree 2: the affected individual carries a previously reported variant co-locating with the variant observed in
pedigree 1, which also disrupts the consensus splice site in CUL3. The lower chromatogram shows that in the affected
individual the wild-type guanine at position c.1377 + 1 (the first base of intron 9 on the border with exon 9) is mutated to
cytosine in a heterozygous manner compared with the wild-type chromatogram above. The position of this variant is shown
in more detail in Figure S5 and full genetic co-ordinates are detailed in Table 1 of the main text. Pedigree 3: the affected
individual carries a previously unreported splice region variant close to a consensus splice site at the border of exon 9 in
CUL3. The lower chromatogram of CUL3 shows that in the affected individual the wild-type thymine,12 bases into intron
8 from the exon 9 border position c.1207, is mutated to adenine in a heterozygous manner compared with the wild-type
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Figure S3 Continued
chromatogram above. The position of this variant is shown in more detail in Figure S5 and full genetic co-ordinates are
detailed in Table 1 of the main text. Pedigree 4: the affected individual carries a previously reported variant disrupting
a consensus splice site at the border of exon 9 in CUL3. The lower chromatogram of CUL3 shows that in the affected
individual the wild-type guanine, one base into intron 8 from the exon 9 border position c.1207, is mutated to adenine in
a heterozygous manner compared with the wild-type chromatogram above. The position of this variant is shown in more
detail in Figure S5 and full genetic co-ordinates are detailed in Table 1 of the main text. Pedigree 5: the affected individual
carries a previously reported FHHt-associated missense variant in KLHL3. The lower chromatogram of KLHL3 shows that
in the affected individual the wild-type guanine is mutated to thymine in a homozygous manner compared with the wild-type
chromatogram. This leads to exon 13 of KLHL3 encoding the amino acid mutation G500V. The position of this mutation
is shown in more detail in Figure S4 and full genetic co-ordinates are detailed in Table 1 of the main text. Pedigree 6:
the affected individual carries a previously reported FHHt-associated missense variant in KLHL3. The lower chromatogram
of KLHL3 shows that in the affected individual the wild-type thymine is mutated to cytosine in a heterozygous manner
compared with the wild-type chromatogram. This leads to exon 10 of KLHL3 encoding the amino acid change L387P. The
position of this mutation is shown in more detail in Figure S4 and full genetic co-ordinates are detailed in Table 1 of the
main text. Pedigree 7: the affected individual carries a previously reported FHHt-associated missense variant in KLHL3.
The lower chromatogram of KLHL3 shows that in the affected individual the wild-type thymine is mutated to cytosine in
a heterozygous manner compared with the wild-type chromatogram. This leads to exon 10 of KLHL3 encoding the amino
acid mutation L387P. The position of this mutation is shown in more detail in Figure S4 and full genetic co-ordinates are
detailed in Table 1 of the main text. Pedigree 8: the affected individual carries a previously reported FHHt-associated
missense variant in KLHL3. The lower chromatogram of KLHL3 shows that in the affected individual the wild-type thymine
is mutated to cytosine in a heterozygous manner compared with the wild-type chromatogram. This leads to exon 10 of
KLHL3 encoding the amino acid mutation L387P. The position of this mutation is shown in more detail in Figure S4 and full
genetic co-ordinates are detailed in Table 1 of the main text. Pedigree 9: the affected individual carries a previously reported
FHHt-associated missense variant in KLHL3. The lower chromatogram of KLHL3 shows that in the affected individual the
wild-type cytosine is mutated to thymine in a heterozygous manner compared with the wild-type chromatogram. This leads
to exon 9 of KLHL3 encoding the amino acid mutation A340V. The position of this mutation is shown in more detail in
Figure S4 and full genetic co-ordinates are detailed in Table 1 of the main text. Pedigree 10: the affected individual carries
a previously reported FHHt-associated missense variant in KLHL3. The lower chromatogram of KLHL3 shows that in the
affected individual the wild-type cytosine is mutated to thymine in a heterozygous manner compared with the wild-type
chromatogram. This leads to exon 13 of KLHL3 encoding the amino acid mutation A494T. The position of this mutation is
shown in more detail in Figure S4 and full genetic co-ordinates are detailed in Table 1 of the main text.
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Figure S4 A schematic diagram illustrating the location of FHHt-associated variants in the KLHL3 protein
Variants identified in the present study are highlighted in red. KLHL3 variants cluster in the kelch domains. The domain
structure of KLHL3 includes BTB [BR-C (Broad Complex), ttk (tramtrack) and bab (bric a brac)], BACK and C-terminal kelch
domains.
Figure S5 CUL3 variants found in affected individuals with FHHt cluster at exon 9 splice sites and cause skipping of
this exon
The 17 exons of CUL3 are depicted and the CUL3 variants associated with FHHt clustering at either end of the exon 9
borders are shown. Positions found mutated in the present study are coloured red.
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Table S1 Genomic DNA targets amplified by the Fluidigm
Access ArrayTM for the CUL3, KLHL3 and SLC4A8 genes
Gene Amplicon number Location
KLHL3 KLHL3_t1 Chr5:136961441–136961585
KLHL3 KLHL3_t2 Chr5:136957785–136957815
KLHL3 KLHL3_t3 Chr5:136963985–136964126
KLHL3 KLHL3_t4 Chr5:136969725–136969854
KLHL3 KLHL3_t5 Chr5:136972982–136973084
KLHL3 KLHL3_t6 Chr5:136974641–136974839
KLHL3 KLHL3_t7 Chr5:136975548–136975666
KLHL3 KLHL3_t8 Chr5:136993819–136993969
KLHL3 KLHL3_t9 Chr5:136997603–136997720
KLHL3 KLHL3_t10 Chr5:137013233–137013343
KLHL3 KLHL3_t11 Chr5:137027973–137028136
KLHL3 KLHL3_t12 Chr5:137033975–137034097
KLHL3 KLHL3_t13 Chr5:137045438–137045545
KLHL3 KLHL3_t14 Chr5:137056153–137056273
KLHL3 KLHL3_t15 Chr5:137071321–137071336
CUL3 CUL3_t1 Chr2:225449660–225449727
CUL3 CUL3_t2 Chr2:225422375–225422573
CUL3 CUL3_t3 Chr2:225400244–225400358
CUL3 CUL3_t4 Chr2:225379328–225379489
CUL3 CUL3_t5 Chr2:225378240–225378355
CUL3 CUL3_t6 Chr2:225376070–225376299
CUL3 CUL3_t7 Chr2:225371574–225371720
CUL3 CUL3_t8 Chr2:225370672–225370849
CUL3 CUL3_t9 Chr2:225368368–225368539
CUL3 CUL3_t10 Chr2:225367681–225367789
CUL3 CUL3_t11 Chr2:225365079–225365204
SLC4A8 SLC4A8_t21 Chr12:51888728–51888902
SLC4A8 SLC4A8_t22 Chr12:51890770–51890963
SLC4A8 SLC4A8_t23 Chr12:51897812–51897904
SLC4A8 SLC4A8_t24 Chr12:51899618–51899714
SLC4A8 SLC4A8_t25 Chr12:51901209–51901223
CUL3 CUL3_t12 Chr2:225362469–225362566
CUL3 CUL3_t13 Chr2:225360548–225360683
SLC4A8 SLC4A8_t1 Chr12:51818770–51818819
SLC4A8 SLC4A8_t2 Chr12:51834491–51834573
SLC4A8 SLC4A8_t3 Chr12:51844659–51844806
Table S1 Continued
Gene Amplicon number Location
SLC4A8 SLC4A8_t4 Chr12:51845907–51846043
SLC4A8 SLC4A8_t5 Chr12:51847322–51847483
SLC4A8 SLC4A8_t6 Chr12:51851134–51851323
SLC4A8 SLC4A8_t7 Chr12:51852342–51852434
SLC4A8 SLC4A8_t8 Chr12:51853734–51853892
SLC4A8 SLC4A8_t9 Chr12:51854987–51855075
SLC4A8 SLC4A8_t10 Chr12:51856093–51856240
SLC4A8 SLC4A8_t11 Chr12:51857397–51857498
SLC4A8 SLC4A8_t12 Chr12:51863397–51863572
SLC4A8 SLC4A8_t13 Chr12:51864175–51864309
SLC4A8 SLC4A8_t14 Chr12:51865070–51865316
SLC4A8 SLC4A8_t15 Chr12:51868125–51868231
SLC4A8 SLC4A8_t16 Chr12:51868828–51868990
SLC4A8 SLC4A8_t17 Chr12:51879570–51879684
SLC4A8 SLC4A8_t18 Chr12:51882482–51882644
SLC4A8 SLC4A8_t19 Chr12:51883483–51883735
SLC4A8 SLC4A8_t20 chr12:51887487–51887556
Table S2 Transcript and protein identities used for the variant
descriptions in the present study
GAN, gigatoxin; KBTBD13, kelch repeat and BTB (POZ) domain-contain-
ing 13; KLHL, kelch-like.
Gene Ensembl transcript Ensembl protein
WNK1 ENST00000315939 ENSP00000313059
WNK4 ENST00000246914 ENSP00000246914
CUL3 ENST00000264414 ENSP00000264414
KLHL3 ENST00000309755 ENSP00000312397
SLC4A8 ENST00000453097 ENSP00000405812
GAN ENST00000248272 ENSP00000248272
SLC4A1 ENST00000262418 ENSP00000262418
KLHL10 ENST00000293303 ENSP00000293303
KLHL7 ENST00000339077 ENSP00000343273
SLC4A4 ENST00000340595 ENSP00000344272
KLHL9 ENST00000359039 ENSP00000351933
SLC4A11 ENST00000380056 ENSP00000369396
CUL5 ENST00000393094 ENSP00000376808
CUL4B ENST00000404115 ENSP00000384109
KBTBD13 ENST00000432196 ENSP00000388723
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